Table 5. Factors affecting adherence to treatment (logistic regression analysis).

Variable	MPR ≥ 0.80		MPR ≥ 0.75		MPR ≥ 0.70
	Odds ratio	p-value	Odds ratio	p-value	Odds ratio	p-value
DUT-TAM FDC vs. AB/5ARI free combination therapy	1.28	< 0.001	1.29	< 0.001	1.30	< 0.001
Prescriber specialty at index date: Urology	1.01	0.621	1.02	0.212	1.03	0.166
Prescriber specialty at index date: Others	1.07	0.069	1.10	0.018	1.09	0.037
Prescriber specialty at index date: GP	Reference		Reference		Reference
Age ≤ 60	Reference		Reference		Reference
Age 61 – 70	1.01	0.651	1.03	0.399	1.02	0.573
Age 71 – 80	1.08	0.012	1.07	0.018	1.05	0.152
Age > 80	1.18	< 0.001	1.19	< 0.001	1.17	< 0.001
Index year 2011	Reference		Reference		Reference
Index year 2012	0.96	0.109	0.96	0.123	0.98	0.359
Index year 2013	0.90	0.001	0.90	< 0.001	0.90	< 0.001
Index year 2014	0.99	0.572	0.99	0.687	0.99	0.628
Index year 2015	1.08	0.003	1.09	0.001	1.11	< 0.001
Prior treatment with 5ARI	0.95	0.008	0.97	0.071	0.97	0.131
Duration of prior AB treatment: naïve	Reference		Reference		Reference
Duration of prior AB treatment: ≤ 12 months	1.06	< 0.001	1.07	< 0.001	1.09	< 0.001
Duration of prior AB treatment: 12 – 24 months	1.18	< 0.001	1.21	< 0.001	1.23	< 0.001
Duration of prior AB treatment: > 24 months	1.40	< 0.001	1.44	< 0.001	1.48	< 0.001
Maximal number of ATC classes: 0	0.53	< 0.001	0.52	< 0.001	0.52	< 0.001
Maximal number of ATC classes: 1 – 3	0.70	< 0.001	0.69	< 0.001	0.68	< 0.001
Maximal number of ATC classes: 4 – 5	0.89	0.002	0.90	0.004	0.89	0.003
Maximal number of ATC classes: 6 – 8	0.99	0.835	0.99	0.822	0.99	0.755
Maximal number of ATC classes: > 8	Reference		Reference		Reference

5ARI = 5-α reductase inhibitor; AB = α-blocker; ATC = anatomical therapeutic chemical; DUT-TAM = dutasteride-tamsulosin; FDC = fixed-dose combination; GP = general practitioner; MPR = medication possession ratio.